Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling

Elvira Sondo, Valeria Tomati, Emanuela Caci, Alessia Isabella Esposito, Ulrich Pfeffer, Nicoletta Pedemonte, Luis J. V. Galietta


The F508del mutation, the most frequent in cystic fibrosis (CF), impairs the maturation of the CFTR chloride channel. The F508del defect can be partially overcome at low temperature (27°C) or with pharmacological correctors. However, the efficacy of correctors on the mutant protein appears to be dependent on the cell expression system. We have used a bronchial epithelial cell line, CFBE41o−, to determine the efficacy of various known treatments and to discover new correctors. Compared with other cell types, CFBE41o− shows the largest response to low temperature and the lowest one to correctors such as corr-4a and VRT-325. A screening of a small-molecule library identified 9-aminoacridine and ciclopirox, which were significantly more effective than corr-4a and VRT-325. Analysis with microarrays revealed that 9-aminoacridine, ciclopirox, and low temperature, in contrast to corr-4a, cause a profound change in cell transcriptome. These data suggest that 9-aminoacridine and ciclopirox act on F508del-CFTR maturation as proteostasis regulators, a mechanism already proposed for the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). However, we found that 9-aminoacridine, ciclopirox, and SAHA, in contrast to corr-4a, VRT-325, and low temperature, do not increase chloride secretion in primary bronchial epithelial cells from CF patients. These conflicting data appeared to be correlated with different gene expression signatures generated by these treatments in the cell line and in primary bronchial epithelial cells. Our results suggest that F508del-CFTR correctors acting by altering the cell transcriptome may be particularly active in heterologous expression systems but markedly less effective in native epithelial cells.

  • cystic fibrosis
  • drug discovery
  • high-throughput screening
  • pharmacological chaperone
  • cystic fibrosis transmembrane conductance regulator

cystic fibrosis (CF), one of the most frequent genetic diseases among people of Caucasian origin, is caused by mutations in the gene coding for CFTR, a protein with Cl channel function (26, 32). CFTR belongs to the superfamily of ATP-binding cassette (ABC) transporters, which includes multidrug-resistance proteins (32). Similarly to many other ABC transporters, CFTR has twelve transmembrane segments and two nucleotide-binding domains (NBD1 and NBD2). In addition, CFTR has an additional domain, called R, which is a substrate for the cAMP-dependent protein kinase A. CFTR channel opening requires phosphorylation of the R domain and binding of two ATP molecules at the interface between NBD1 and NBD2 (32). CFTR represents a major route for Cl transport in epithelial cells of the airways and other organs. Defective CFTR function severely impairs mucociliary transport in the respiratory system, thus favoring the colonization of airway surfaces by pathogenic bacteria.

Nearly 1,500 mutations have been identified among CF patients, but the most frequent molecular defect (70–90%) is the absence of phenylalanine 508 (F508del) in NBD1 (26). F508del causes a major trafficking defect in the CFTR protein, which is largely unable to exit the endoplasmic reticulum and is rapidly degraded by the proteasome complex (18, 39, 44). Although a small fraction of F508del-CFTR reaches the plasma membrane, its half-life on the cell surface is significantly shorter than that of the wild-type protein (24, 39). The F508del mutation is also responsible for a decreased channel activity (gating defect). Even under conditions inducing maximal phosphorylation, the time spent by F508del-CFTR in the Cl-conducting state is nearly threefold shorter than the wild-type protein (14).

An intensive research is being conducted to find drugs able to restore the function of mutant CFTR to treat CF patients (40). Chemical compounds called potentiators are able to ameliorate the gating defect of F508del and of other mutations (e.g., G551D). Other compounds, labeled as CFTR correctors, are potentially able to improve the trafficking of the F508del mutant. Several potentiators have been identified by various strategies, including high-throughput screening (30, 40, 43). Their activity is independent of cell background and probably based on direct interaction with CFTR itself (31). A potentiator, VX-770, is already in phase 3 clinical trials on CF patients with CFTR channel gating defect (1, 37). Instead, the identification of correctors (29, 38) appears much more problematic (31). Indeed, F508del-CFTR is detected by multiple cellular checkpoints as a misfolded protein and tagged for degradation (44). Because of this redundant quality control, it is not clear whether a single pharmacological molecule will be effective in rescuing the mutant protein.

F508del correctors may work as pharmacological chaperones, i.e., by directly binding the mutant protein and favoring its folding and maturation. Alternatively, correctors may also work as proteostasis regulators by modifying the cell proteome favoring mutant CFTR maturation (27, 41). The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA), which modifies the cell transcriptome by altering the expression of several genes, has been recently found to rescue F508del-CFTR (15).

Identification of effective potentiators and correctors by high-throughput screening requires the use of cell lines since primary epithelial cells are not suitable for large-scale studies. However, cell lines may have intrinsic limitations due to differences in the proteome relative to primary cells. These cell-dependent differences may affect the efficacy of compounds, particularly of correctors.

In a previous study, we have compared the effect of potentiators and correctors in two different cell models, Fischer rat thyroid (FRT) and A549 cells, expressing F508del-CFTR. While potentiators appeared equally active in the two systems, correctors were strongly cell type dependent, with most compounds being active in only one of the two cell lines (31). Our results suggest that activity of correctors in cell lines used for heterologous expression are not predictive of efficacy in primary airway epithelial cells of CF patients. We asked whether a better cell model can be identified.

In the present study, we have evaluated CFBE41o−, a cell line derived by immortalization from the bronchial epithelium of a CF patient homozygous for F508del mutation (11, 22). This cell line has been subsequently engineered to express detectable amounts of wild-type and F508del-CFTR (2). We wondered whether CFBE41o− cells may be useful to identify novel correctors by small-molecule screening. We have found that CFBE41o− cells show a high level of F508del-CFTR rescue by incubation at low temperature and, in contrast, a low sensitivity to known pharmacological correctors. In addition to low temperature, CFBE41o− cells are also very responsive to small molecules acting by modification of the cell transcriptome, including SAHA, 9-aminoacridine, and ciclopirox. However, these treatments are ineffective in primary airway epithelial cells. Our results suggest that the potential activity of proteostasis regulators on F508del rescue may be overestimated in recombinant cell expression systems.


Cell culture.

The CF bronchial epithelial cells, CFBE41o−, with stable expression of F508del-CFTR or wild-type CFTR, were obtained by Dr. J. P. Clancy (2). A549 and FRT cells were stable transfected with a plasmid coding for F508del-CFTR and carrying the resistance gene for zeocin. The three cell types were also transfected with the halide-sensitive yellow fluorescent protein (HS-YFP) YFP-H148Q/I152L (8). The culture media were as follows: Coon's modified Ham's F-12 medium for FRT cells, DMEM/Ham's F-12 (1:1) for A549 cells, and MEM for CFBE41o−. All media were supplemented with 10% fetal calf serum, 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. For fluorescence assays of CFTR activity, FRT, A549, and CFBE41o− cells were plated (50,000 cells/well) on clear-bottom 96-well black microplates (Corning Life Sciences, Acton, MA). For short-circuit current experiments, 500,000 CFBE41o− cells were seeded into Snapwell permeable supports (Corning Life Sciences).

Primary human bronchial epithelial cells from F508del/F508del CF patients were cultured as previously described (9, 28). Briefly, cells were initially cultured on plastic in proliferative serum-free medium, LHC9/RPMI 1640, and then cultured on Snapwell supports for 10–12 days with a differentiating medium. The isolation of airway epithelial cells from the lung of CF patients undergoing a lung transplant was approved by The Regional Ethics Committee.

HS-YFP assay for CFTR activity.

Measurements of CFTR activity were carried out on CFBE41o−, FRT, and A549 cells expressing mutant F508del-CFTR and the HS-YFP 48 h after plating on microplates. Twenty-four hours after plating, the cells were incubated with test compounds at 37°C for 20 to 24 h. At the time of assay, cells were washed with PBS (containing 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, and 0.5 mM MgCl2) and stimulated for 30 min with forskolin (20 μM) plus genistein (50 μM). Then, cells were transferred to a microplate reader (FluoStar Galaxy; BMG Labtech, Offenburg, Germany) for CFTR activity determination. The plate reader was equipped with high-quality excitation (HQ500/20X: 500 ± 10 nm) and emission (HQ535/30M: 535 ± 15 nm) filters for YFP (Chroma Technology, Brattleboro, VT). Each assay consisted of a continuous 14-s fluorescence reading with 2 s before and 12 s after injection of an iodide-containing solution (PBS with Cl replaced by I; final I concentration in the well: 100 mM). Data were normalized to the initial background-subtracted fluorescence. To determine fluorescence quenching rate associated with I influx, the final 11 s of the data for each well were fitted with an exponential function to extrapolate initial slope (dF/dt).

Transepithelial Cl current measurements.

Experiments on CFBE41o− cells were performed 5–6 days after seeding, by mounting the Snapwell inserts in a self-contained Ussing chamber system (vertical diffusion chamber; Corning Life Sciences). Transepithelial currents were measured using a transepithelial Cl gradient. Accordingly, the basolateral solution contained (in mM) 126 NaCl, 0.38 KH2PO4, 2.1 K2HPO4, 1 MgSO4, 1 CaCl2, 24 NaHCO3, and 10 glucose. The apical solution had similar composition except for a lower NaCl concentration (63 mM NaCl) and the presence of 63 mM sodium gluconate. During experiments, solutions in both chambers were continuously bubbled with a mixture of 5% CO2 in air. The hemichambers were connected to DVC-1000 voltage clamps (World Precision Instruments, Sarasota, FL) via Ag/AgCl electrodes and 1 M KCl agar bridges. Transepithelial currents were digitized using PowerLab 4/25 data acquisition systems and stored on a personal computer. All measurements were done at 37°C. In contrast to HS-YFP experiments, stimulation of F508del-CFTR in transepithelial current recordings was done with 8-(4-chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (CPT-cAMP) and felodipine because currents were more stable than with the forskolin plus genistein cocktail. Conditions for recordings on primary bronchial epithelial cells were similar except that some experiments were performed with the high-NaCl solution on both sides of the epithelium, whereas others were performed with the Cl gradient as for CFBE41o− cells.

Immunoprecipitation and Western blot analysis.

Cells grown on 100-mm diameter dishes were lysed in lysis buffer (20 mM HEPES pH 7, 150 mM NaCl, 1 mM EGTA, 1% Igepal) containing Complete Protease Inhibitor Cocktail (Roche, NJ). After preclearing of lysates with pansorbin (Calbiochem), CFTR was immunoprecipitated in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing 2 mM Mg-ATP, using a mouse monoclonal anti-CFTR COOH-terminal antibody (24–1, R&D Systems) and pansorbin. The immunoprecipitates were subjected to SDS-PAGE and analyzed by Western blotting. Proteins were immunodetected by a mouse monoclonal anti-CFTR antibody (M3A7, Millipore) followed by horseradish peroxidase-conjugated anti-mouse IgG, and visualized by chemiluminescence with the LiteAblot Turbo kit (Euroclone). Direct recording of the chemiluminescence was performed using the Molecular Imager ChemiDoc XRS System, and quantification was performed with ImageJ software (National Institutes of Health, Bethesda, MD).

HDAC activity assay.

Histone deacetylase activity was measured with the Fluor-de-Lys-green fluorimetric HDAC assay kit (Enzo Life Sciences) according to the manufacturer's instructions.

Gene expression analysis by microarrays.

Total RNAs were isolated from treated or untreated cells (CFBE41o− cells plated on petri dishes, primary bronchial epithelial cells plated on Snapwell supports) using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Oligo(dT)-primed cDNAs were synthesized using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Irvine, CA) following the manufacturer's instructions. For microarray analysis, double-stranded cDNAs were synthesized using the Custom SuperScript Double-Stranded cDNA Synthesis Kit (Invitrogen) and extracted with phenol-chloroform-isoamyl alcohol (25:24:1), ethanol precipitated, and used to prepare cRNAs using the Bioarray High Yield RNA Transcription Kit (Affymetrix, Santa Clara, CA) according to the manufacturer's instructions. cRNAs were purified using the RNeasy Mini Kit (Qiagen), controlled by agarose gel electrophoresis, and subjected to fragmentation for 35 min at 94°C in fragmentation buffer [40 mM Tris-acetate pH 8.1, 100 mM CH3COOH, 30 mM Mg(CH3COO)].

Labeled cRNA was used for screenings of GeneChip Human Genome U133plus2 arrays (Affymetrix). Three to four biological replicates were analyzed for each condition. Hybridization and scanning was performed on the Affymetrix platform. Data were normalized following the GCRMA procedure (16) of Bioconductor 1.4 ( (45). Statistically significant expression changes were determined using permutation tests (SAM;∼tibs/SAM/) implemented in MeV software (33, 36). Genes regulated at least twofold in comparison to untreated controls were considered. The delta value was set to return a median false significant number < 1. Annotations were obtained through the DAVID database ( (7).

Expression of CFTR mRNA was also evaluated by real-time RT-PCR as described previously (28).

Statistical analysis.

Data are shown as representative experiments or as means ± SE. Statistical significance of differences between groups of data was assessed with ANOVA.


We used engineered CFBE41o− cells derived by lentiviral transduction of F508del or wild-type CFTR (2) because the expression of the endogenous CFTR gene in the parental cell line is too low to be detected by most functional assays. In short-circuit current experiments (Fig. 1), CFBE41o− cells expressing F508del-CFTR showed very little response to cAMP agonists and potentiators such as CPT-cAMP and felodipine, respectively (Fig. 1A). After stimulation, total F508del-CFTR activity was evaluated by applying CFTRinh-172 (10 μM), a selective CFTR inhibitor (4, 25). The decrease in short-circuit current caused by the inhibitor was almost negligible (∼1 μA/cm2), thus indicating that the expression level of F508del-CFTR in the plasma membrane is very low. Cell incubation for 24 h with corr-4a (5 μM), a F508del corrector that is quite effective in other cell systems (29), caused only a nonsignificant 50% increase in CFTRinh-172 effect (Fig. 1, A and C). On the other hand, CFBE41o− cells were highly responsive to low temperature. Incubation at 27°C for 24 h markedly increased CFTR activity by >10-fold, as evident from the enhanced response to CPT-cAMP, felodipine, and CFTRinh-172 (Fig. 1, A and C). Interestingly, low-temperature incubation had also the ability to make the cells much more responsive to the corrector. Indeed, the rescue elicited by corr-4a increased significantly from 50% at 37°C to ∼ 250% at 27°C (Fig. 1, A and C).

Fig. 1.

Rescue of F508del-CFTR function by corr-4a and low temperature. Transepithelial Cl currents were measured in CFBE41o− cells expressing F508del or wild-type (WT) CFTR. A: representative recordings showing response of F508del-CFTR to acute application of 8-(4-chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (CPT-cAMP; 200 μM), felodipine (5 μM), and inh-172 (10 μM). Cells were kept for 24 h under control conditions or treated with corr-4a (c4, 5 μM) and/or low temperature (27°C). B: representative experiments from cells expressing wild-type CFTR. CFTRinh-172 was applied after or before (gray trace) stimulation with CPT-cAMP plus felodipine. C: summary of data from transepithelial Cl current experiments. Total CFTR activity was evaluated by measuring the amplitude of the current inhibited by inh-172 (n = 19–29; **P < 0.01).

CFBE41o− cells expressing wild-type CFTR showed very large transepithelial Cl currents under resting conditions (>50 μA/cm2). Stimulation with CPT-cAMP and felodipine caused a relatively small (∼ 20–30%) increase in current (Fig. 1B). Subsequent application of CFTRinh-172 reduced Cl currents to nearly zero. These results indicate that a large fraction of CFTR is already active under resting conditions, a characteristic also shown by primary airway epithelial cells (5). This conclusion was supported by experiments in which CFTRinh-172 was applied before stimulation (Fig. 1B, gray trace). Application of CFTRinh-172 caused a strong decrease of the current close to the zero level. Subsequent stimulation with CPT-cAMP plus felodipine elicited a total current (8.5 ± 0.7 μA/cm2, n = 6) which was much smaller than that measured in the absence of the inhibitor (71.8 ± 2.0 μA/cm2, n = 4, P < 0.01).

We generated a fluorescent version of CFBE41o−/F508del cells by stable transfection with HS-YFP. These cells allowed to rapidly test the effect of correctors by simply measuring I influx (29, 30, 43). The HS-YFP data confirmed the observations obtained with the short-circuit current technique. Cells kept at 37°C had almost undetectable activity, even after maximal stimulation with forskolin (to elevate intracellular cAMP) and with the potentiator genistein (Fig. 2, A and C). Treatment for 24 h with corr-4a or another corrector, VRT-325, caused a modest (∼60%) F508del rescue that did not reach statistical significance (Fig. 2, A and C). However, incubation of cells at low temperature strongly increased anion transport (∼ 15-fold), and this effect was further enhanced by corr-4a or VRT-325 (Fig. 2, B and D), thus confirming the results obtained with the short-circuit current technique.

Fig. 2.

Sensitivity of cells expressing F508del-CFTR to rescue maneuvers. F508del-CFTR activity was measured with the halide-sensitive yellow fluorescent protein (HS-YFP) assay. A and B: representative traces showing cell fluorescence decay upon extracellular addition of I. CFBE41o− cells expressing F508del-CFTR were kept at 37°C (A) or at 27°C (B) for 24 h with or without corr-4a (5 μM) or VRT-325 (10 μM). C and D: bars report the fluorescence quenching rate (QR) from experiments as those shown in A and B, respectively (n = 6–8; **P < 0.01 vs. control). E: comparison of HS-YFP assay data obtained in Fischer rat thyroid (FRT), A549, and CFBE41o− cells expressing F508del-CFTR. Data are reported as fold increase of QR by rescue maneuvers (n = 10–12).

Using the HS-YFP, we also compared the sensitivity to F508del rescue maneuvers in CFBE41o−, A549, and FRT cells (Fig. 2E). The data confirm the peculiar behavior of CFBE41o− cells, which are highly responsive to low-temperature rescue. In contrast, FRT cells had the minimal response to low temperature, compared with the other two cell lines (Fig. 2E).

To further evaluate CFBE41o− as a cell line suitable for the identification of F508del correctors, we used the YFP assay to perform a pilot screening of 2,534 small molecules containing a large fraction of Food and Drug Administration-approved drugs (31). These compounds were tested by cell incubation at 37°C for 24 h. The screening detected essentially two active compounds: 9-aminoacridine and ciclopirox. At 5 and 20 μM, the optimal concentrations, these two compounds enhanced F508del-CFTR activity (anion transport) by 3.3- and 2.9-fold, respectively (Fig. 3, A and B). For comparison, we evaluated the activity of SAHA, an HDAC inhibitor (HDACi), that has been recently identified in CFBE41o− cells as a F508del corrector (15). Under our conditions, SAHA (5 μM) increased anion transport by 2.2-fold (Fig. 3, A and B), a result comparable to that reported previously (15). The effects of 9-aminoacridine and SAHA were confirmed with the short-circuit current technique. Incubation with 9-aminoacridine (10 μM) or SAHA (5 μM) increased total F508del-CFTR activity (i.e., the current sensitive to CFTRinh-172) by eight- and threefold, respectively (Fig. 3, CF). These experiments were not possible with ciclopirox since this compound decreased transepithelial resistance of CFBE41o− cells (R < 200 Ω·cm2 vs. 660 ± 40 Ω·cm2 for control; 585 ± 85 Ω·cm2 for corr-4a; 925 ± 175 Ω·cm2 for 9-aminoacridine; 625 ± 85 Ω·cm2 for 27°C).

Fig. 3.

Rescue of F508del-CFTR by novel compounds. A and B: representative traces and summary of QR from HS-YFP assays on CFBE41o− cells expressing F508del-CFTR. Cells were treated with indicated compounds: 9-aminoacridine (9-AC, 5 μM), ciclopirox (CPX, 20 μM), and suberoylanilide hydroxamic acid (SAHA; 5 μM) (n = 5–12; *P < 0.05). CF: representative recordings of transepithelial Cl currents (CE) and amplitude of inh-172-sensitive current (F) from CFBE41o− cells expressing F508del-CFTR treated with and without 9-AC or SAHA (n = 6–10; *P < 0.05).

To obtain information on the mechanism of the different rescue treatments, we performed a global gene expression analysis using microarrays. We treated CFBE41o− cells for 24 h with corr-4a (5 μM), ciclopirox (20 μM), 9-aminoacridine (5 μM), and low temperature (27°C). After RNA extraction, we determined gene expression profile using GeneChip Human Genome U133 plus two arrays (Affymetrix). As shown in Fig. 4, A and B, 9-aminoacridine and ciclopirox caused a profound change in gene expression, with the former compound eliciting a particularly dramatic effect. This is evident from the large scattering of data points, indicating that several hundred genes were markedly upregulated or downregulated by the treatment. In contrast, incubation with corr-4a produced relatively small gene expression changes (Fig. 4C). This is also shown in Fig. 5A, which reports the fold-increase for the top 100 genes upregulated by each treatment. For 9-aminoacridine and ciclopirox, the first 100 genes were upregulated by more than 100- and 30-fold, respectively (Fig. 5A). Instead, the largest effect of corr-4a was an eight- to fourfold increase, restricted only to the top 20 genes (see also Supplemental Tables S1–S4; Supplemental Material for this article is available online at the Journal website). A similar pattern is also evident by looking at the genes downregulated by each treatment: 9-aminoacridine and ciclopirox, but not corr-4a, caused a dramatic decrease in the expression of several genes (Tables S5–S8). In other words, 9-aminoacridine and ciclopirox are very pleiotropic substances, causing a global change in the cell transcriptome. Surprisingly, incubation of cells at low temperature also evoked a wide effect on gene expression, qualitatively comparable to that of 9-aminoacridine and ciclopirox (Figs. 4D and 5A and Tables S3 and S7). We looked at the list of the most upregulated and downregulated genes by the four different treatments, looking for a possible overlap (Fig. 5C). The only gene upregulated by all treatments was PTGS2 (i.e., cyclooxygenase 2). This finding can be explained by the behavior of PTGS2 as an inducible gene lying downstream various signaling cascades. Among the most affected genes (i.e., the 100 genes most upregulated or downregulated), we found 50 other genes being affected by more than one treatment. Concordant genes were not clearly suggestive of a common mechanism of action.

Fig. 4.

Global effects of F508del-CFTR rescue maneuvers on gene expression in CFBE41o− cells. Cells were treated with 9-aminoacridine (5 μM; A), ciclopirox (20 μM; B), corr-4a (5 μM; C), or low temperature (D). Each dot in the graph reports the expression level for a given gene after treatment vs. the expression level in untreated cells (mean of three separate cell preparations). Data were obtained with gene expression microarrays.

Fig. 5.

Analysis of gene expression changes by F508del-CFTR rescue maneuvers. A: extent of gene expression changes by 9-aminoacridine (5 μM), ciclopirox (20 μM), low temperature, and corr-4a (5 μM). For every treatment, the top 100 upregulated genes were selected. The graph reports the fold increase for each one of these genes. Data are from the gene expression microarrays shown in Fig. 4. B: fold increase in CFTR mRNA caused by rescue maneuvers, as determined by real-time RT-PCR (n = 3; *P < 0.05; **P < 0.01 vs. corr-4a). C: the two-panel report, among the 100 most upregulated genes (left) or downregulated genes (right), the ones common to more than one treatment.

We have inspected the identity of genes modulated by correctors and low temperature to obtain possible indications about the underlying molecular mechanisms (Tables S1–S8). The effect of 9-aminoacridine consists of a massive upregulation or downregulation of several genes, which seem to be largely unrelated to each other. For example, the list reported in Table S1 includes hemoglobin A1 and A2. These genes are essentially silent under resting conditions, as expected from an epithelial cell line, but become highly active after treatment with 9-aminoacridine. These characteristics suggest that 9-aminoacridine is a general inducer of gene transcription. Interestingly, CFTR transcript was also strongly upregulated by 9-aminoacridine (∼ 60-fold, position 253 in the list of upregulated genes). This result was confirmed by real-time RT-PCR (65-fold upregulation of CFTR transcript by 9-aminoacridine, Fig. 5B). Therefore, the rescue by 9-aminoacridine may be a consequence of the strong increase in F508del-CFTR protein synthesis and escape from the endoplasmic reticulum by mass action. However, we cannot exclude that other proteins, also affected by 9-aminoacridine, contribute to F508del rescue. Given the very strong and general effect of 9-aminoacridine on gene transcription, we hypothesized that it acts as an HDACi similarly to SAHA. We performed an assay using a commercially-available kit (Fig. 6A). The results show clearly that 9-aminoacridine has no HDACi activity, in contrast to positive controls SAHA and trichostatin A.

Fig. 6.

Mechanism of action of F508del-CFTR rescue maneuvers. A: histone deacetylase activity in the presence of indicated compounds (n = 3; **P < 0.01 vs. control). TSA, trichostatin A; AU, arbitrary units. B: F508del-CFTR activity (QR) in CFBE41o− after treatment with desferoxamine (DFX, 200 μM), 1,4-DPCA (50 μM), or 2,4-DPD (20 μM) (n = 8–21; *P < 0.05). Data were obtained by incubating the cells with compounds for 24 h at 37°C.

Ciclopirox and low temperature also have a global effect on cell transcriptome that includes upregulation of CFTR gene expression. Indeed, the mutant CFTR transcript was upregulated by eight- and fivefold, respectively (Fig. 5B). However, compared with 9-aminoacridine, these compounds may trigger a more specific transcriptional program. Regarding low temperature, it has been reported that cells exposed to moderate hypothermia show a cold shock response that modifies the proteostasis environment (10). Indeed, the list in Table S3 includes various genes related to protein synthesis and degradation. Some of the genes induced at 27°C may be particularly relevant to F508del-CFTR processing, such as deubiquitylating enzymes (e.g., USP15 and USP36, 18-fold and 10-fold increase, respectively). Among the genes downregulated by low temperature, AHSA2 (homolog of Aha1; Table S7) was particularly interesting (>6-fold decrease). Inhibition of Aha1 by small interfering RNA was found in another study to result in F508del-CFTR rescue (41).

Ciclopirox is instead known as an iron-chelating agent and, consequently, an inducer of the hypoxia-inducible factor 1α (HIF-1α) cascade (23). This transcription factor is controlled by a panel of oxygen-sensing and iron-dependent enzymes, the prolyl hydroxylases (PHDs). The prolyl hydroxylation of HIF-1α is responsible for its degradation through the proteasome (20). Under hypoxic conditions, PHDs are inhibited, thus allowing stabilization of HIF-1α and induction of the corresponding transcriptional response. Therefore, the mechanism of ciclopirox as a F508del corrector may involve the triggering of a response mimicking the hypoxic condition with altered expression of several genes. Indeed, many genes reported to be induced by hypoxia in other studies, such as ATF3, BTG2, NDRG-1, BMP2, and RGS2 (3, 6, 17, 35), are present among the ones upregulated by ciclopirox (Supplemental Table S2). To verify this link, we tested various pharmacological modulators acting on the hypoxia-induced pathway. We found that another iron-chelating agent, desferoxamine, also increases the function of F508del-CFTR (Fig. 6B). Furthermore, we found that the PHD inhibitors 1,4-DPCA and 2,4-DPD are active in rescuing F508del-CFTR activity.

In contrast to the other treatments, corr-4a had little consequence on gene expression. Evaluation of the few genes upregulated or downregulated by this corrector (Tables S4 and S8) did not reveal a signature associated with a known biological response.

We also investigated the effect of different rescue maneuvers by determining the electrophoretic mobility maturation of F508del-CFTR protein (Fig. 7). Cells lysates were processed by immunoprecipitation followed by Western blot analysis. In control conditions at 37°C, F508del-CFTR is mostly revealed as band B (∼ 150 kDa) representing the core-glycosylated form of the protein residing in the endoplasmic reticulum (Fig. 7A, third lane). Cells expressing wild-type CFTR instead show the fully glycosylated mature form of the protein, band C, migrating at ∼ 180 kDa (Fig. 7A, second lane). At 37°C, the various treatments did not significantly increase the maturation of F508del-CFTR. Actually, SAHA and 9-aminoacridine caused an increase in band B intensity alone. Improvements in F508del-CFTR maturation were mostly seen at low temperature as indicated by the increase in band C/(band B + band C) value [C/(B + C)] (Fig. 7B). At 27°C, the relative abundance of band C was significantly increased, although the extent of rescue was still far from reaching the pattern of wild-type CFTR, as also shown previously (2). Treatment with corr-4a (5 μM), VRT-325 (10 μM), ciclopirox (20 μM), or 9-aminoacridine (10 μM) at low temperature further improved F508del-CFTR maturation. Instead, SAHA caused a marked inhibition of C/(B + C) value at low temperature (Fig. 7, B and C). We also tested 1,4-DPCA and 2,4-DPD. These compounds did not significantly improve CFTR protein maturation (not shown).

Fig. 7.

Biochemical analysis of F508del-CFTR protein maturation. A: representative immunoprecipitation/Western blot experiments on cell lysates from CFBE41o− cells expressing F508del-CFTR, wild-type CFTR, or from parental (null) cells. Cells were treated with indicated compounds (5 μM corr-4a, 10 μM VRT-325, 5 μM SAHA, 20 μM ciclopirox, or 5–10 μM 9-aminoacridine) at 37°C or 27°C for 24 h. The content of actin in each lysate was determined by Western blot analysis. B: summary of data expressed as the ratio of band C/(band B + band C) intensity (n = 4–5; *P < 0.05 vs. control; ††P < 0.01 vs. control at 37°C).

We checked the efficacy of different compounds and low temperature in primary bronchial epithelial cells from a homozygous F508del patient (Fig. 8). The effective treatments were corr-4a, VRT-325, and low temperature, although the extent of correction was relatively modest (1.7-, 2.1-, and 2.3-fold increase, respectively). In contrast, SAHA, 9-aminoacridine, ciclopirox, 1,4-DPCA, and 2–4-DPD were ineffective (Fig. 8, A and B). Actually, SAHA and 9-aminoacridine significantly decreased the CFTR-dependent current. Such negative findings were also confirmed in experiments in which a Cl gradient was applied to increase the driving force for Cl secretion (Fig. 8C). We asked whether the failure of some compounds in increasing CFTR-dependent Cl secretion was due to a decrease in transepithelial resistance. Resistance was measured with an epithelial voltohmeter. None of the treatments significantly decreased the resistance (control: 2,060 ± 37 Ω·cm2; corr-4a: 2,180 ± 76 Ω·cm2; 9-aminoacridine: 1,905 ± 171 Ω·cm2; ciclopirox: 2,177 ± 48 Ω·cm2; 27°C: 2,048 ± 37 Ω·cm2). Similar results were also obtained by calculating the resistance from the Ohm's law using the values of short-circuit current and transepithelial potential difference measured in the Ussing chamber.

Fig. 8.

Evaluation of rescue maneuvers in primary bronchial epithelia. A: representative short-circuit current recordings performed on cultured primary bronchial epithelial cells from F508del cystic fibrosis (CF) patients. The experiments were performed in symmetrical Cl. B: inh-172-sensitive current after treatment of bronchial epithelial cells with indicated conditions. Data are from the set of experiments shown in A. Each bar is the mean ± SE of 8–21 experiments. Corr-4a (5 μM), VRT-325 (10 μM), and low temperature significantly increased the current (*P < 0.05 vs. control). Instead, SAHA (5 μM) and 9-aminoacridine (5 μM) cause a significant inhibition (†P < 0.05 vs. control). C: inh-172-sensitive current from short-circuit current experiments performed with a Cl gradient (n = 5–6; *P < 0.05 vs. control).

We analyzed gene expression with microarrays also in primary bronchial epithelial cells (Fig. 9). The effect of low temperature and ciclopirox was qualitatively similar to that observed in CFBE41o− cells in that a large number of genes showed altered expression (1,418 genes for 27°C and 554 for ciclopirox; see Fig. 10). However, the incubation at low temperature produced a very interesting result. There was remarkable overlap of the genes affected by low temperature in both cell types (97% of the genes affected by low temperature in primary cells were also present in the CFBE41o− list; Fig. 10). This is also evident from the list of the 100 most upregulated or downregulated genes (Tables S3 and S7). Genes involved in protein quality control and degradation (in particular USP15, USP36, and AHSA2) were strongly affected in both cell types. The extent of concordant genes was smaller for ciclopirox (64% of genes modulated by ciclopirox in primary cells were also present in the CFBE41o− list). In contrast, a striking difference was noted for 9-aminoacridine. This compound had a relatively small activity in bronchial epithelial cells (compare Figs. 4 and 9). In this respect, it is important to take into account that some differences in our results could be due to the conditions used before extraction of RNA for microarray analysis (cells on solid support for CFBE41o− vs. cells on permeable support for primary epithelial cells). Corr-4a was also characterized by a small effect on gene expression in primary cells, but this result was consistent with the findings obtained in CFBE41o− cells. Interestingly, none of the treatments increased CFTR expression in primary bronchial epithelial cells (not shown) as instead observed in CFBE41o− cells for 9-aminoacridine, ciclopirox, and low temperature.

Fig. 9.

Gene expression profiling in human bronchial epithelial (BE) cells. Cells were treated with 9-aminoacridine (5 μM; A), ciclopirox (20 μM; B), corr-4a (5 μM; C), or low temperature (D). Each dot in the graph reports the expression level for a given gene after treatment vs. the expression level in untreated cells (mean of four separate cell preparations). Data were obtained with gene expression microarrays.

Fig. 10.

Comparison of gene expression signatures in CFBE41o− and primary bronchial epithelial cells. Data are from the experiments shown in Figs. 4 and 9. The Venn diagrams report the number of genes with altered expression (2-fold increase or decrease) by each one of the indicated treatments and the number of the commonly affected genes in the two types of cells.


Identification of effective F508del correctors is a major goal of CF research given the frequency and severity of this mutation. This search could be helped by the knowledge of the relevant molecular targets and mechanisms involved in F508del-CFTR protein misprocessing and degradation, but the existing information is not yet sufficient to proceed with a rational design/search of F508del correctors. Therefore, one of the most reasonable approaches to find active compounds is the screening of chemical libraries using a functional or biochemical readout (40). However, this process may be strongly affected by the cell type used for the screening. In contrast to the search for CFTR potentiators, the screening for correctors appears to be markedly affected by the cell background (31). Using a cell line that is as close as possible to the native cells expressing F508del-CFTR in vivo seems the most logical solution.

In the present study, we have evaluated the bronchial cell line CFBE41o− that has become a popular cell model in CF research. In particular, we used an engineered version of the cell line that has increased expression of wild-type or F508del-CFTR (2, 19, 39). Compared with other cell models previously used for high-throughput screenings, we found that CFBE41o− cells are poorly sensitive to F508del correctors such as corr-4a but strongly responsive to low-temperature treatment. However, the incubation at 27°C seems to shift the cells to a “permissive” state that is much more sensitive to the effect of correctors. It has been recently shown that corr-4a acts only when the F508del-CFTR protein is fully synthesized (13), and possibly by also stabilizing the protein at the plasma membrane (39). It has been also shown that F508del-CFTR is detected by the cell quality control systems and largely degraded when its synthesis is not complete (13, 44). Therefore, the poor rescue by corr-4a and other known correctors in CFBE41o− may be explained by a tighter quality control compared with other cells that instead appear less stringent. In “leaky” cells, such as FRT, a significant amount of mutant protein may escape from the degradation pathway and be amenable to the action of correctors (29). The particularly strong effect of low temperature in CFBE41o− cells, which increases the efficacy of corr-4a and VRT-325, may be due to a stabilization of the mutant protein and a slowing down of degradation. Therefore, understanding the mechanism of low temperature and mimicking it with a small molecule appears as an important priority to design novel maneuvers for F508del rescue. Indeed, such maneuvers would act at early levels, before nascent F508del-CFTR is tagged for degradation. Our gene expression analysis with microarrays reveals that the low-temperature treatment has a complex effect since it causes a profound alteration in cell transcriptome. Therefore, it is probable that the corresponding change in the proteostasis environment, and not the activity/expression of a single protein, is globally responsible for F508del-CFTR rescue by low temperature. Nevertheless, as discussed in a subsequent paragraph, low temperature has also a marked effect on CFTR mRNA levels in CFBE41o− cells.

To assess the suitability of CFBE41o− cells as a model to identify correctors, we performed a pilot screening of a chemical library using the HS-YFP assay. One of the active compounds detected in the screening was 9-aminoacridine. This compound elicited a marked rescue of F508del-CFTR function in CFBE41o− cells. As for low temperature, we found that 9-aminoacridine causes a dramatic upregulation of hundreds of genes. Therefore, 9-aminoacridine appears as a nonspecific inducer of gene expression. We hypothesized that this compound works as a histone deacetylase inhibitor (HDACi) similarly to SAHA, which has been found to rescue F508del-CFTR (15). However, 9-aminoacridine was completely inactive in a HDAC assay. Therefore, this compound acts on gene expression with a different mechanism. It is possible that 9-aminoacridine works as a DNA-threading agent (12, 46). The effect on chromatin structure may be responsible for the global gene transcription effect that also results in increased synthesis of the transfected F508del-CFTR.

The screening of the chemical library also detected ciclopirox as a possible corrector. Interestingly, a similar screening on A549 cells expressing F508del-CFTR also identified ciclopirox (31). The results obtained with desferoxamine and PHD inhibitors suggest that ciclopirox acts by activating the HIF-1α cascade. This biological process involves a change in expression and activity of many proteins (hypoxic response). One or more of these proteins could affect F508del-CFTR processing, probably in an indirect way. For example, it has been shown that EGLN3 causes the prolyl hydroxylation and direct degradation of the β-adrenergic receptor (42). A similar process may also occur for CFTR.

Surprisingly, we found that 9-aminoacridine, ciclopirox, and low temperature also cause a marked upregulation of CFTR mRNA in CFBE41o− cells. This effect was also reported previously for SAHA in the same cells (15). Therefore, it is not clear how much of the rescue is due to F508del-CFTR upregulation vs. modification of proteostasis environment. The increase in mutant protein expression could cause the escape from the endoplasmic reticulum by mass action leading to an overestimation of the real effect on F505del-CFTR maturation. Indeed, SAHA, 9-aminoacridine, and ciclopirox appeared ineffective when tested in primary bronchial epithelial cells from F508del patients. The reason for the high sensitivity of F508del-CFTR expression to a variety of treatments in CFBE41o− cells is not clear but it is possible that the viral elements used to drive expression of transfected CFTR are sensitive to different types of chemical or physical cell stress as reported previously (21, 34).

Analysis of gene expression in primary bronchial epithelial cells provided useful information to understand the mechanisms of the different F508del rescue maneuvers and to explain the failure of some molecules as correctors in primary cells. Both ciclopirox and low temperature were confirmed as treatments causing a broad effect on cell transcriptome. Low temperature was particularly interesting because it caused a very similar effect in CFBE41o− and primary bronchial epithelial cells, with several genes being equally affected in both cell types. Interestingly, none of the treatments caused a change in CFTR mRNA levels in primary bronchial epithelial cells. This finding further indicates that the peculiar activity of 9-aminoacridine and ciclopirox in CFBE41o− as “apparent correctors” may be explained in large part by their effect on CFTR expression. This conclusion may be true also for SAHA.

In summary, our results suggest that the failure of some F508del rescue maneuvers in primary bronchial epithelial cells correlates with different gene expression signatures generated by these treatments in cell lines and primary cells. For example, the most effective F508del rescue maneuvers in CFBE41o− cells are the ones associated with global effects on cell transcriptome, such as 9-aminoacridine, SAHA, ciclopirox, and low temperature. In theory, these treatments may promote a change in the cell proteome, particularly in the CFTR protein interactome (41), thus creating an environment that is more favorable for F508del-CFTR maturation. However, we found that some treatments do not have the same effect on the cell transcriptome of primary cells, which may explain their lack of efficacy as correctors. In particular, the upregulation of CFTR protein expression observed in CFBE41o− but not in primary cells may lead to an overestimation of F508del-CFTR corrector activity.

Despite its global effect on cell transcriptome in general and on heterologous CFTR in particular, rescue by low temperature appears as an interesting phenomenon to investigate. Indeed, in contrast to 9-aminoacridine, ciclopirox, and SAHA, low temperature improves by itself F508del-CFTR protein maturation, synergizes with correctors, and is effective in primary cells. Rescue of F508del-CFTR at 27°C has also another interesting feature, as discussed above. Our gene expression profiling has revealed that the gene expression signatures generated at low temperature in CFBE41o− and primary cells are very similar, thus suggesting the existence of a cell type-independent response to hypothermia. Dissection of molecular events underlying rescue by low temperature may lead to improved strategies for CF therapy. For example, genes affected by low temperature could be upregulated/silenced individually or in combination to assess their effect on F508del-CFTR. In the present study, we have paid attention to the most affected genes by each treatment. However, in future studies, analysis of genes with less dramatic upregulation or downregulation may also provide useful information.

In conclusion, CFBE41o− cells are potentially an interesting cell model to identify F508del correctors. In particular, CFBE41o− are less “leaky” than other cell lines and therefore may be useful to find correctors acting at early steps of CFTR protein processing, thus preventing its premature degradation. However, CFBE41o− cells are also particularly sensitive to treatments increasing gene expression in general and CFTR transcript in particular. This issue needs to be taken into account during the evaluation and prioritization of primary active compounds arising from screenings. Accordingly, future small-molecule screenings on CFBE41o− or similar cells will need to be followed by secondary analysis to categorize putative correctors and to differentiate compounds with more specific mechanism of action from those having general effects on cell transcriptome and proteome.


This work was supported by funds from Cystic Fibrosis Foundation Therapeutics, Telethon Foundation (GGP10026), and Fondazione Italiana Fibrosi Cistica (FFC#2/2009 with the contribution of “Delegazione FFC di Vicenza”). N. Pedemonte is a recipient of a grant to young investigators from the Italian Ministry of Health (GR-2008-1141326).


No conflicts of interest, financial or otherwise, are declared by the author(s).


We thank Dr. J. P. Clancy for kindly providing us with CFBE41o− cells expressing wild-type CFTR and F508del-CFTR.


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
View Abstract